Eli Lilly’s Weight Loss Pill Orforglipron Shows Real Promise in Major Trial

Eli Lilly may be getting closer to putting a weight loss pill on pharmacy shelves. The company recently announced strong results from a large Phase 3 trial of orforglipron. It’s an experimental daily pill designed to work like injectable GLP-1 receptor agonist drugs. Those drugs have already reshaped how doctors treat obesity.

The trial, called ATTAIN-1, enrolled more than 3,100 adults living with obesity or overweight-related health conditions. None of the participants had diabetes. After 72 weeks, people on the highest dose lost an average of 27.3 pounds. That works out to about 12.4% of their starting body weight. Lower doses also delivered meaningful results. Participants lost 7.8% and 9.3% of body weight at the 6 mg and 12 mg doses.

More than half of patients on the top dose lost at least 10% of their body weight. Nearly 40% lost 15% or more.

One practical advantage of orforglipron is how patients take it. Novo Nordisk’s Rybelsus is the only oral GLP-1 currently on the diabetes market. Patients must take it on an empty stomach. They then wait 30 minutes before eating or drinking. Orforglipron carries none of those restrictions. Patients take it once daily with no food timing rules to follow.

That flexibility matters more than it might seem. Medication adherence remains a persistent problem in obesity treatment. Some studies show nearly half of patients stop taking GLP-1 medications within a year. Removing barriers to consistent dosing could make a real difference in outcomes.

The trial also captured improvements in several cardiovascular risk factors. Participants saw reductions in non-HDL cholesterol, triglycerides, and systolic blood pressure. At the highest dose, orforglipron cut high-sensitivity C-reactive protein levels by nearly 48%. Doctors use that protein as a well-established marker of systemic inflammation. Obesity commonly co-occurs with elevated cardiovascular risk, and addressing both simultaneously strengthens the clinical case for the drug.

Side effects followed the pattern doctors already see with injectable GLP-1 drugs. Nausea topped the list of complaints. It affected about 34% of patients on the highest dose, compared to around 10% on placebo. Patients in the treatment groups also reported constipation, diarrhea, and vomiting more often. Most effects stayed mild to moderate. Still, clinicians took note of the discontinuation rates, and researchers will continue to monitor them.

Lilly also shared results from a separate trial called ATTAIN-MAINTAIN. Researchers designed it to find out whether orforglipron could help patients keep weight off after stopping injectable therapy. Participants who had previously taken Wegovy and then switched to the pill gained less than one kilogram over the next 52 weeks. Doctors already know that patients tend to regain weight after stopping GLP-1 injections. An effective oral option for the maintenance phase fills a real gap in long-term care.

Lilly plans to submit orforglipron to the FDA and other global regulators. The company is targeting a possible approval for weight management as early as late 2025. It expects to file for type 2 diabetes approval in 2026. Lilly is also expanding manufacturing capacity ahead of a potential launch.

Orforglipron’s weight loss results sit around 12%, which falls short of what Wegovy and Zepbound typically deliver. Some analysts question how competitive the pill will be in an already crowded market. But many patients find weekly self-injection difficult or simply prefer not to do it. For those people, a straightforward daily pill with no dietary restrictions may be the far more practical option.